Clinical Trials Logo

Filter by:
NCT ID: NCT06325774 Recruiting - Clinical trials for Localized Prostate Cancer

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects. Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.

NCT ID: NCT06325761 Not yet recruiting - Health Subjects Clinical Trials

A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This study is a single-center, randomized, open-label, single-dose, two-period, two-treatment crossover trial aimed at evaluating the pharmacokinetic (PK) profiles and safety of SY-5007 tablets administered orally to healthy subjects in both fasting and fed states in China.

NCT ID: NCT06325605 Completed - Clinical trials for Adolescent Depression

Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

A total of 100 patients with adolescent depression who were admitted to our hospital between March 2022 and October 2022 were selected. On the basis of double blinding, these patients were randomly divided into the observation group(n=50) and the control group(n=50) using a random number table. 5S management method was used in the whole process of treatment to improve the hospital environment, increase the work efficiency and reduce the occurrence of cross infection through the effective implementation of the five steps of sort(Seiri), set in order(Seiton), shine (Seiso), standardize(Seiketsu) and sustain(Shitsuke).

NCT ID: NCT06325592 Completed - Clinical trials for High-Grade Squamous Intraepithelial Lesions

Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL

Start date: October 1, 2023
Phase:
Study type: Observational

This study aimed to analyze perioperative information in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing total hysterectomy (TH), offering insights into optimal surgery timing, selecting the operation path, and enhancing surgical operation details.

NCT ID: NCT06325527 Not yet recruiting - Alzheimer Disease Clinical Trials

Cognitive Impairment Cohort Study of the Elderly Population in YuGarden

Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this prospective observational research with an 8-year follow-up is to study the cognitive changes in the elderly in YuGarden community, Shanghai, China. The main questions it aims to answer are: - incidence of cognitive impairment in community (converting to mild cognitive impairment or Alzheimer's disease) - to build a predictive model for the progression of cognitive impairment

NCT ID: NCT06325267 Recruiting - Clinical trials for Primary Liver Cancer

Clinical Characteristics of Primary Liver Cancer

Start date: January 1, 2010
Phase:
Study type: Observational

Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC.

NCT ID: NCT06325254 Recruiting - Clinical trials for Metabolic Associated Fatty Liver Disease

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

Start date: January 1, 2010
Phase:
Study type: Observational

Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. With the improvement of living standards and changes in dietary habits, MAFLD patients show a younger and increasing trend, but there is still no specific drug. The clinical features and prognosis of MAFLD may be different with different metabolic disorder phenotypes and treatment measures. Therefore, further systematic study of the clinical characteristics and prognosis of MAFLD patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.

NCT ID: NCT06324994 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free triple therapy of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in R/R BV-MCL patients.

NCT ID: NCT06324890 Recruiting - Dry Eye Clinical Trials

PET-CT Imaging Features of Meibomian Glands

Start date: January 31, 2024
Phase:
Study type: Observational

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

NCT ID: NCT06324825 Recruiting - Clinical trials for Atrophic Gastritis With Low-grade Intraepithelial Neoplasia

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Start date: October 24, 2022
Phase: N/A
Study type: Interventional

Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule.